var data={"title":"Norfloxacin (United States: not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Norfloxacin (United States: not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6668?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=norfloxacin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Norfloxacin (United States: not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6758355\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious adverse reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fluoroquinolones are associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue norfloxacin immediately and avoid the use of fluoroquinolones in patients who experience any of these serious adverse reactions. Because fluoroquinolones are associated with serious adverse reactions, reserve norfloxacin for use in patients who have no alternative treatment options for uncomplicated urinary tract infections (including cystitis).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Exacerbation of myasthenia gravis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fluoroquinolonesmay exacerbate muscle weakness in patients with myasthenia gravis. Avoid norfloxacin in patients with known history of myasthenia gravis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202558\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Noroxin [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202559\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Norflox;</li>\n      <li>CO Norfloxacin;</li>\n      <li>PMS-Norfloxacin;</li>\n      <li>Teva-Norfloxacin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202604\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Fluoroquinolone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202563\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Note: </b> Noroxin is no longer available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prostatitis:</b> Oral: 400 mg every 12 hours for 4 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Uncomplicated gonorrhea:</b> Oral: 800 mg as a single dose. <b>Note:</b>  As of April 2007, the CDC no longer recommends the use of fluoroquinolones for the treatment of uncomplicated gonococcal disease. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Urinary tract infections:</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Uncomplicated due to <i>E. coli, K. pneumoniae, P. mirabilis</i>: 400 mg twice daily for 3 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Uncomplicated due to other organisms: 400 mg twice daily for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Complicated: 400 mg twice daily for 10 to 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dysenteric enterocolitis</b> <b><i>(Shigella)</i></b> <b>(off-label use):</b> 400 mg twice daily for 3 days (IDSA 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Spontaneous bacterial peritonitis (SBP) (prevention) (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prior SBP or low protein ascites:</i> Long-term prophylaxis: 400 mg once daily (AASLD [Runyon 2012]; EASL 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Variceal hemorrhage:</i> Short-term prophylaxis: 400 mg every 12 hours for 7 days (AASLD [Runyon 2012]; Fernandez 2006). May also administer norfloxacin 400 mg every 12 hours for 7 days after a course of IV ceftriaxone during active GI bleed (AASLD [Runyon 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Traveler's diarrhea (off-label use):</b> 400 mg twice daily for 3 days (Mattila 1993), single dose may also be effective.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202564\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202565\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\"> CrCl &le;30 mL/minute/1.73 m<sup>2</sup>: 400 mg once daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20210562\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202532\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Noroxin: 400 mg [DSC]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202518\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29031928\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral: 400 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29245365\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Noroxin is no longer available in the US.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874936\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM246795.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68V9/EgNBrv0UE93thWMzrTw==&amp;TOPIC_ID=9710\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM246795.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202536\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Hold antacids, sucralfate, or multivitamins/supplements containing iron, zinc, magnesium, or aluminum for at least 2 hours before or after giving norfloxacin; do not administer together. Administer on an empty stomach with water (at least 1 hour before or 2 hours after meals, milk, or other dairy products).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202535\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Uncomplicated and complicated urinary tract infections caused by susceptible gram-negative and gram-positive bacteria; sexually transmitted disease (eg, uncomplicated urethral and cervical gonorrhea) caused by <i>N. gonorrhoeae</i>; prostatitis due to <i>E. coli</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> As of April 2007, the CDC no longer recommends the use of fluoroquinolones for the treatment of gonococcal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Because fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions (eg, tendinitis and tendon rupture, peripheral neuropathy, CNS effects), reserve norfloxacin for use in patients who have no alternative treatment options for acute uncomplicated urinary tract infections.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469460\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Infectious Diarrhea; Spontaneous bacterial peritonitis (prevention); Shigella dysentery type 1; Traveler's diarrhea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202611\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Norfloxacin may be confused with Norflex, Noroxin [DSC]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Noroxin [DSC] may be confused with Neurontin, Norflex</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202525\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (2% to 3%), headache (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (3% to 4%), abdominal cramping (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Eosinophilia (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Liver enzymes increased (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&ge;0.3% to 1%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drowsiness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Hyperhidrosis, pruritus, rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased WBC count (1%), increased serum alkaline phosphatase (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain, anorectal pain, anorexia, constipation, diarrhea, dyspepsia, flatulence, loose stools, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Proteinuria (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic and oncologic: Decreased platelet count (1%), leukopenia (1%), thrombocytopenia (1%), decreased hematocrit, decreased hemoglobin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (1%), back pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;0.3%, postmarketing, and/or case reports: Abdominal swelling, acute renal failure, agranulocytosis, albuminuria, anaphylactoid reaction, anaphylaxis, angioedema, anxiety, arthralgia, arthritis, ataxia, bitter taste, blurred vision, bursitis, candiduria, casts in urine, chest pain, chills, cholestatic jaundice, <i>Clostridium difficile</i>-associated diarrhea, confusion, crystalluria, depression, diplopia, DRESS syndrome, dysgeusia, dysmenorrhea, dyspnea, edema, erythema, erythema multiforme, exacerbation of myasthenia gravis, exfoliative dermatitis, gastrointestinal hemorrhage, glycosuria, Guillain-Barr&eacute; syndrome, hearing loss, heartburn, hematuria, hemolytic anemia (sometimes associated with G6PD deficiency), hepatic failure, hepatic necrosis, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), hypercholesterolemia, hyperglycemia, hyperkalemia, hypersensitivity angiitis, hypersensitivity reaction, hypertriglyceridemia, hypoesthesia, hypoglycemia, increased blood urea nitrogen, increased creatine phosphokinase, increased intracranial pressure, increased lactate dehydrogenase, increased serum creatinine, insomnia, interstitial nephritis, jaundice, muscle spasm, myalgia, myocardial infarction, myoclonus, neutropenia, nystagmus, oral mucosa ulcer, orthostatic hypotension, palpitations, pancreatitis (rare), paresthesia, peripheral edema, peripheral neuropathy (may be irreversible), phototoxicity, prolonged prothrombin time, prolonged Q-T interval on ECG, pruritus ani, pseudotumor cerebri, psychotic reaction, renal colic, rupture of tendon, seizure, skin photosensitivity, Stevens-Johnson syndrome, stomatitis, tendonitis, tingling of the fingers, tinnitus, torsades de pointes, toxic epidermal necrolysis, tremor, urticaria, uveitis, vasculitis, ventricular arrhythmia, vulvovaginal candidiasis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202539\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to norfloxacin, quinolones, or any component of the formulation; history of tendonitis or tendon rupture associated with quinolone use </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202522\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered cardiac conduction: Fluoroquinolones may prolong QTc interval; avoid use in patients with a history of QTc prolongation, uncorrected hypokalemia, hypomagnesemia, or concurrent administration of other medications known to prolong the QT interval (including Class Ia and Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, and tricyclic antidepressants).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glucose regulation: Fluoroquinolones have been associated with the development of serious, and sometimes fatal, hypoglycemia. These events have occurred most often in elderly patients with diabetes, but have also been reported in patients without a prior history of diabetes. Prompt identification and treatment of hypoglycemia is essential. Individual quinolones may differ in their potential to cause this effect. It was most evident with gatifloxacin (no longer marketed as s systemic formulation). Hyperglycemia has also been associated with the use of fluoroquinolones. Patients should be monitored closely for signs/symptoms of disordered glucose regulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phototoxicity: Avoid excessive sunlight and take precautions to limit exposure (eg, loose fitting clothing, sunscreen); may cause moderate-to-severe phototoxicity reactions. Discontinue use if photosensitivity occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serious adverse reactions:<b> [US Boxed Warning]: Fluoroquinolones are associated with disabling and potentially irreversible serious adverse reactions that may occur together, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue norfloxacin immediately and avoid use of fluoroquinolones in patients who experience any of these serious adverse reactions.</b> Patients of any age or without pre-existing risk factors have experienced these reactions; may occur within hours to weeks after initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- CNS effects: Fluoroquinolones have been associated with an increased risk of CNS effects including seizures, increased intracranial pressure (including pseudotumor cerebri), and toxic psychosis; may also cause nervousness, agitation, insomnia, anxiety, nightmares, paranoia, dizziness, confusion, tremors, hallucinations, depression, and suicidal thoughts or actions. May occur following the first dose; discontinue immediately and avoid further use of fluoroquinolones in patients who experience these reactions. Use with caution in patients with known or suspected CNS disorder, or risk factors that may predispose to seizures or lower the seizure threshold.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Peripheral neuropathy: Fluoroquinolones have been associated with an increased risk of peripheral neuropathy; may occur soon after initiation of therapy and may be irreversible; discontinue if symptoms of sensory or sensorimotor neuropathy occur. Avoid use in patients who have previously experienced peripheral neuropathy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Tendinitis/tendon rupture: Fluoroquinolones have been associated with an increased risk of tendonitis and tendon rupture in all ages; risk may be increased with concurrent corticosteroids, solid organ transplant recipients, and in patients &gt;60 years of age, but has also occurred in patients without these risk factors. Rupture of the Achilles tendon has been reported most frequently; but other tendon sites (eg, rotator cuff, biceps, hand) have also been reported. Inflammation and rupture may occur bilaterally. Cases have been reported within hours or days of initiation, and up to several months after discontinuation of therapy. Strenuous physical activity, renal failure, and previous tendon disorders may be independent risk factor for tendon rupture. Discontinue at first sign of tendon pain, swelling, inflammation or rupture. Avoid use in patients with a history of tendon disorders or who have experienced tendinitis or tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: <b>[US Boxed Warning]: May exacerbate muscle weakness related to myasthenia gravis; avoid use in patients with known history of myasthenia gravis.</b> Cases of severe exacerbations, including the need for ventilatory support and deaths have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution with renal impairment; dose adjustment required. May increase risk of tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may increase risk of tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syphilis: Since norfloxacin is ineffective in the treatment of syphilis and may mask symptoms, all patients should be tested for syphilis at the time of gonorrheal diagnosis and 3 months later.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Adverse effects (eg, tendon rupture, QT changes) may be increased in the elderly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; G6PD deficiency: Hemolytic reactions may (rarely) occur with quinolone use in patients with latent or actual G6PD deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull;  Pediatric: Safety and efficacy have not been established in children; other quinolones have caused transient arthropathy in children.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <b>[US Boxed Warning]: Reserve use of norfloxacin for treatment of uncomplicated urinary tract infections, including cystitis, for patients who have no alternative treatment options because of the risk of disabling and potentially serious adverse reactions (eg, tendinitis and tendon rupture, peripheral neuropathy, CNS effects).</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202599\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202527\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9710&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Quinolones. Of concern only with oral administration of quinolones. Management: Avoid concurrent administration of quinolones and antacids to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone.<b> Exceptions: </b>Sodium Bicarbonate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Glucose Lowering Agents: Quinolones may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caffeine and Caffeine Containing Products: Norfloxacin may increase the serum concentration of Caffeine and Caffeine Containing Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the absorption of Quinolones. Of concern only with oral administration of both agents.<b> Exceptions: </b>Calcium Chloride.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Norfloxacin may decrease the metabolism of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delamanid: Quinolones may enhance the QTc-prolonging effect of Delamanid.  Management: Avoid concomitant use of delamanid and quinolone antibiotics if possible. If coadministration is considered to be unavoidable, frequent monitoring of electrocardiograms (ECGs) throughout the full delamanid treatment period should occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Quinolones may decrease the serum concentration of Didanosine. Didanosine may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heroin: Quinolones may enhance the adverse/toxic effect of Heroin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, oflox-, pefloxacin, or nalidixic acid) oral iron salts<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Quinolones. Management: Administer oral quinolone antibiotics at least one hour before or four hours after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Quinolones. Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolones. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Quinolones. Specifically, minerals in the multivitamin/mineral product may impair absorption of quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Quinolones may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nadifloxacin: May enhance the adverse/toxic effect of Quinolones.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitrofurantoin: May diminish the therapeutic effect of Norfloxacin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May decrease the excretion of Quinolones. Specifically, probenecid may decreased the renal excretion of quinolone antibiotics. Probenecid may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinapril: May decrease the serum concentration of Quinolones. Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sevelamer: May decrease the absorption of Quinolones. Management: Administer oral quinolones at least 2 hours before or 6 hours after sevelamer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strontium Ranelate: May decrease the serum concentration of Quinolones. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the serum concentration of Quinolones. Management: Administer oral quinolones at least 2 hours before or 6 hours after the sucralfate dose.  Greater separation of doses may further lessen the risk for a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Quinolones may decrease the metabolism of Theophylline Derivatives. Ciprofloxacin and enoxacin are of greatest concern.  Theophylline/quinolone therapy might augment the seizure-producing potential of each of the individual agents. <b> Exceptions: </b>Dyphylline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varenicline: Quinolones may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Quinolones may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zinc Salts: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, pe- or ofloxacin or nalidixic acid) oral zinc salts.<b> Exceptions: </b>Zinc Chloride.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202554\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Norfloxacin average peak serum concentrations may be decreased if taken with food or dairy products. Management: Administer on an empty stomach with water at least 1 hour before or 2 hours after meals, milk, or other dairy products.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202529\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202542\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Norfloxacin crosses the placenta, distributing to cord blood and amniotic fluid (Wise 1984). Based on available data, an increased risk of teratogenic effects has not been observed following norfloxacin use during pregnancy (Bar-Oz 2009; Padberg 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202543\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Norfloxacin was not detected in the milk of nursing mothers administered an oral 200 mg dose. It is not known if concentrations would be detectable after a higher dose or multiple doses. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202544\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Oral formulations should be administered on an empty stomach with water (at least 1 hour before or 2 hours after meals, milk, or other dairy products). Maintain fluid intake to ensure adequate hydration and urinary output.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15577086\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor CBC, renal and hepatic function periodically if therapy is prolonged.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202521\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Norfloxacin is a DNA gyrase inhibitor. DNA gyrase is an essential bacterial enzyme that maintains the superhelical structure of DNA. DNA gyrase is required for DNA replication and transcription, DNA repair, recombination, and transposition; bactericidal</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202538\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Rapid, up to 40%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 10% to 15%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 3 to 4 hours; Renal impairment (CrCl &le;30 mL/minute): 6.5 hours; Elderly: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (26% to 32% as unchanged drug; 5% to 8% as metabolites); feces (30%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202541\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Noroxin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (20): $96.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F202545\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ambigram (CO, DO, GT, HN, PA, SV);</li>\n      <li>Anquin (IL);</li>\n      <li>Ansor (ET);</li>\n      <li>Apiflox (AE, JO, KW, QA);</li>\n      <li>Baccidal (JP, KR, TW);</li>\n      <li>Barazan (DE);</li>\n      <li>Bexinor (SG);</li>\n      <li>Biofloxin (IN);</li>\n      <li>Chibroxin (AE, BR, CN, CY, EG, ES, HR, IQ, IR, JO, LB, LY, OM, PE, PL, QA, SA, SY, VE, YE);</li>\n      <li>Chibroxine (BH, FR, KW, UY);</li>\n      <li>Chibroxol (LU, PT);</li>\n      <li>Ectalin (UY);</li>\n      <li>Euroflox (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Flox (BR);</li>\n      <li>Floxacin (AT, CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Fluseminal (GR);</li>\n      <li>Fulgram (CL);</li>\n      <li>Gonorcin (TH);</li>\n      <li>Gyrablock (AE, BH, CY, CZ, EG, ET, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Janacin (HK, MY, TH);</li>\n      <li>Laxifloxin (AU);</li>\n      <li>Lexinor (BD, CL, ID, IN, JP, PK, SE, TW);</li>\n      <li>M-Flox (TH);</li>\n      <li>Manoflox (TH);</li>\n      <li>Microxin (MX);</li>\n      <li>Mitatonin (HK);</li>\n      <li>Myfloxin (TH);</li>\n      <li>Naflox (LB);</li>\n      <li>Negaflox (BG, ET, LK);</li>\n      <li>Nolicin (CZ, EE, HR, HU, LT, LV, PL, RU, SI, SK);</li>\n      <li>Nolitsyn (UA);</li>\n      <li>Noracin (JO, QA);</li>\n      <li>Norax (QA);</li>\n      <li>Norbactin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TH, TN, TZ, UG, ZM, ZW);</li>\n      <li>Norbactin Eye Drops (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Norf (BR);</li>\n      <li>Norflohexal (DE);</li>\n      <li>Norflox (DE, IN, LV);</li>\n      <li>Norflox Eye (IN);</li>\n      <li>Norfloxin (MY);</li>\n      <li>Norfloxin-400 (ZW);</li>\n      <li>Norlox (ZW);</li>\n      <li>Normac (LK);</li>\n      <li>Normaks (UA);</li>\n      <li>Normax (LK);</li>\n      <li>Normax Eye Ear Drops (IN);</li>\n      <li>Noroxin (AE, AR, BB, BF, BH, BJ, BM, BS, BZ, CI, CN, CY, ET, FI, GH, GM, GN, GY, IT, JM, JO, KE, KW, LB, LK, LR, MA, ML, MR, MU, MW, MX, NE, NG, NL, PE, PK, PT, QA, SA, SC, SD, SL, SN, SR, TN, TR, TT, TZ, UG, VE, ZM, ZW);</li>\n      <li>Noroxin Oftalmico (MX);</li>\n      <li>Noroxine (FR);</li>\n      <li>Norsol (CH);</li>\n      <li>Norulox (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Nufloxib (AU);</li>\n      <li>Oprelex (JO);</li>\n      <li>Oranor (MX);</li>\n      <li>Orsanac (EC, PY);</li>\n      <li>Roxin (AU);</li>\n      <li>Sefnor (TH);</li>\n      <li>Sofasin (GR);</li>\n      <li>Uridon (PY);</li>\n      <li>Uriflox (ET);</li>\n      <li>Urigen (CO);</li>\n      <li>Urobacid (EC, JO);</li>\n      <li>Uroctal (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Uroflox (ET, IN, PT);</li>\n      <li>Uronor (UY);</li>\n      <li>Uroxacin (AR);</li>\n      <li>Uroxin (AE, BH, KW, LB, QA, SA);</li>\n      <li>UT-in (ZA);</li>\n      <li>Winaflox (PH);</li>\n      <li>Xacin (TH);</li>\n      <li>Xasmun (ES);</li>\n      <li>Zoroxin (AT, BE, LU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bar-Oz B, Moretti ME, Boskovic R, O'Brien L, Koren G. The safety of quinolones--a meta-analysis of pregnancy outcomes. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2009;143(2):75-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/19181435 /pubmed\" target=\"_blank\" id=\"19181435 \">19181435 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhattacharya SK and Sur D, &ldquo;An Evaluation of Current Shigellosis Treatment,&rdquo; <i>Expert Opin Pharmacother</i>, 2003, 4(8):1315-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/12877639/pubmed\" target=\"_blank\" id=\"12877639\">12877639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &ldquo;Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections,&rdquo; <i>MMWR Recomm Rep</i>, 2007, 56(14):332-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/17431378/pubmed\" target=\"_blank\" id=\"17431378\">17431378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. <i>J Hepatol</i>. 2010;53(3):397-417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/20633946/pubmed\" target=\"_blank\" id=\"20633946\">20633946</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fern&aacute;ndez J, Ruiz del Arbol L, G&oacute;mez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. <i>Gastroenterology</i>. 2006;131(4):1049-1056.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/17030175/pubmed\" target=\"_blank\" id=\"17030175\">17030175</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedrich LV and Dougherty R, &ldquo;Fatal Hypoglycemia Associated With Levofloxacin,&rdquo; <i>Pharmacotherapy</i>, 2004, 24(12):1807-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/15585448/pubmed\" target=\"_blank\" id=\"15585448\">15585448</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frothingham R, &ldquo;Glucose Homeostasis Abnormalities Associated With Use of Gatifloxacin,&rdquo; <i>Clin Infect Dis</i>, 2005, 41(9):1269-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/16206101/pubmed\" target=\"_blank\" id=\"16206101\">16206101</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gavin JR 3rd, Kubin R, Choudhri S, et al, &ldquo;Moxifloxacin and Glucose Homeostasis: A Pooled-Analysis of the Evidence From Clinical and Postmarketing Studies,&rdquo; <i>Drug Saf</i>, 2004, 27(9):671-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/15230648/pubmed\" target=\"_blank\" id=\"15230648\">15230648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graumlich JF, Habis S, Avelino RR, et al, &ldquo;Hypoglycemia in Inpatients After Gatifloxacin or Levofloxacin Therapy: Nested Case-Control Study,&rdquo; <i>Pharmacotherapy</i>, 2005, 25(10):1296-302.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/16185172/pubmed\" target=\"_blank\" id=\"16185172\">16185172</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guerrant RL, Van Gilder T, Steiner TS, et al, &quot;Practice Guidelines for the Management of Infectious Diarrhea,&quot; <i>Clin Infect Dis</i>, 2001, 32(3):331-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/11170940/pubmed\" target=\"_blank\" id=\"11170940\">11170940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hooper DC and Wolfson JS, &ldquo;Fluoroquinolone Antimicrobial Agents,&rdquo; <i>N Engl J Med</i>, 1991, 324(6):384-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/1987461/pubmed\" target=\"_blank\" id=\"1987461\">1987461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khaliq Y and Zhanel GG, &ldquo;Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature,&rdquo; <i>Clin Infect Dis</i>, 2003, 36(11):1404-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/12766835/pubmed\" target=\"_blank\" id=\"12766835\">12766835</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lawrence KR, Adra M, and Keir C, &ldquo;Hypoglycemia-Induced Anoxic Brain Injury Possibly Associated With Levofloxacin,&rdquo; <i>J Infect</i>, 2006, 52(6):e177-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/16269178/pubmed\" target=\"_blank\" id=\"16269178\">16269178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lo WY and Friedman JM, &ldquo;Teratogenicity of Recently Introduced Medications in Human Pregnancy,&rdquo; <i>Obstet Gynecol</i>, 2002, 100(3):465-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/12220765/pubmed\" target=\"_blank\" id=\"12220765\">12220765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loebstein R, Addis A, Ho E, et al, &ldquo;Pregnancy Outcome Following Gestational Exposure to Fluoroquinolones: A Multicenter, Prospective Controlled Study,&rdquo; <i>Antimicrob Agents Chemother</i>, 1998, 42(6):1336-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/9624471/pubmed\" target=\"_blank\" id=\"9624471\">9624471</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lomaestro BM and Bailie GR, &ldquo;Quinolone-Cation Interactions: A Review,&rdquo; <i>DICP</i>, 1991, 25(11):1249-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/1763542/pubmed\" target=\"_blank\" id=\"1763542\">1763542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malone RS, Fish DN, Abraham E, et al, &ldquo;Pharmacokinetics of Levofloxacin and Ciprofloxacin During Continuous Renal Replacement Therapy in Critically Ill Patients,&rdquo; <i>Antimicrob Agents Chemother</i>, 2001, 45(10):2949-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/11557500/pubmed\" target=\"_blank\" id=\"11557500\">11557500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mattila L, Peltola H, Siitonen A, et al, &quot;Short-Term Treatment of Traveler's Diarrhea With Norfloxacin: A Double-Blind, Placebo-Controlled Study During Two Seasons,&quot; <i>Clin Infect Dis</i>, 1993, 17(4):779-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/8268363/pubmed\" target=\"_blank\" id=\"8268363\">8268363</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mohr JF, McKinnon PS, Peymann PJ, et al, &ldquo;A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone,&rdquo; <i>Pharmacotherapy</i>, 2005, 25(10):1303-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/16185173/pubmed\" target=\"_blank\" id=\"16185173\">16185173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nilsson-Ehle I and Ljungberg B, &ldquo;Quinolone Disposition in the Elderly: Practical Implications,&rdquo; <i>Drugs Aging</i>, 1991, 1(4):279-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/1794020/pubmed\" target=\"_blank\" id=\"1794020\">1794020</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Noroxin (norfloxacin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Padberg S, Wacker E, Meister R, et al. Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones. <i>Antimicrob Agents Chemother</i>. 2014;58(8):4392-4398.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/24841264 /pubmed\" target=\"_blank\" id=\"24841264 \">24841264 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park-Wyllie LY, Juurlink DN, Kopp A, et al, &ldquo;Outpatient Gatifloxacin Therapy and Dysglycemia in Older Adults,&rdquo; <i>N Engl J Med</i>, 2006, 354(13):1352-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/16510739/pubmed\" target=\"_blank\" id=\"16510739\">16510739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Runyon BA. Management of adult patients with ascites due to cirrhosis: update 2012. Alexandria, VA: American Association for the Study of Liver Diseases; 2012. http://aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf. Accessed May 12, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stein GE, &ldquo;The 4-Quinolone Antibiotics: Past, Present, and Future,&rdquo; <i>Pharmacotherapy</i>, 1988, 8(6):301-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/2851772/pubmed\" target=\"_blank\" id=\"2851772\">2851772</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Szarfman A, Chen M, and Blum MD, &ldquo;More on Fluoroquinolone Antibiotics and Tendon Rupture,&rdquo; <i>N Engl J Med</i>, 1995, 332(3):193.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo; <i> Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walker RC and Wright AJ, &ldquo;The Fluoroquinolones,&rdquo; <i>Mayo Clin Proc</i>, 1991, 66(12):1249-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/1749294/pubmed\" target=\"_blank\" id=\"1749294\">1749294</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang S and Rizvi AA, &ldquo;Levofloxacin-Induced Hypoglycemia in a Nondiabetic Patient,&rdquo; <i>Am J Med Sci</i>, 2006, 331(6):334-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/16775443/pubmed\" target=\"_blank\" id=\"16775443\">16775443</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA and Berman SM, &quot;Centers for Disease Control and Prevention: Sexually Transmitted Diseases Treatment Guidelines,&quot; <i>MMWR</i>, 2006, 55(RR-11):1-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/norfloxacin-united-states-not-available-drug-information/abstract-text/16888612/pubmed\" target=\"_blank\" id=\"16888612\">16888612</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9710 Version 180.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F6758355\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F202558\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F202559\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F202604\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F202563\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F202564\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F202565\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20210562\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F202532\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F202518\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F29031928\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F29245365\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874936\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F202536\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F202535\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469460\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F202611\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F202525\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F202539\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F202522\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F202599\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F202527\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F202554\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F202529\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F202542\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F202543\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F202544\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F15577086\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F202521\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F202538\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F202541\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F202545\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9710|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=norfloxacin-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Norfloxacin (United States: not available): Patient drug information</a></li></ul></div></div>","javascript":null}